Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

By B. Brenner, M. Cooper, D. Zeeuw, W. Keane, W. Mitch, H. Parving, Giuseppe Remuzzi, S. Snapinn, Zhonxin Zhang, S. Shahinfar. New England Journal of Medicine, 2001

6,186 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism, Nephrology

View Paper: https://www.semanticscholar.org/paper/842bf4da2a50ee13464536c9dfa502f4eb80c5f1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Giuseppe Remuzzi
2. J. Forbes
3. M. Cooper
4. E. Dale Abel
5. S. Laurent
6. Oliver Faust
7. E. Schiffrin
8. V. Basevi

In Endocrinology, Diabetes and Metabolism

1. J. Forbes
2. M. Cooper
3. Nur Samsu
4. V. Basevi

In Nephrology

1. Youhua Liu
2. W. Mitch
3. Giuseppe Remuzzi
4. Nur Samsu
5. V. Basevi

Citations in the corpus

• The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019) (2019, methodology): “Hypertension increases the risk for reduced estimated glomerular filtration rate (eGFR), CKD and end-stage kidney disease (ESKD) [21–24].”
• Molecular mechanisms of diabetic kidney disease. (2014, positive): “Efforts to define glomerular capillary hypertension in rats and maneuvers to mitigate these hemodynamic perturbations (12) culminated in the demonstration that ACE inhibition and separately angiotensin receptor blockers reduced the progression of clinical DKD (13).”
• Mechanisms of diabetic complications. (2013, background): “These findings build on a large body of evidence using AT1 receptor antagonists, which have demonstrated end organ protection in diabetic complications (59).”